Core Viewpoint - The company has completed significant corporate governance changes, including capital restructuring and board adjustments, which are aimed at enhancing operational efficiency and compliance with regulatory requirements [1]. Group 1: Corporate Governance Changes - The company held its fourth board meeting and fourth supervisory board meeting on December 10, 2025, and a second extraordinary shareholders' meeting on December 26, 2025, to approve various governance changes [1]. - The approved changes include alterations to registered capital, cancellation of the supervisory board, adjustments to the number of board members, and amendments to the company's articles of association [1]. Group 2: Registration and Compliance - The company has completed the necessary business registration changes and has received a new business license from the Changsha Market Supervision Administration [1]. - The updated registered capital is set at 13.132 million yuan [1]. - The company operates as a joint-stock company with a focus on pharmaceutical research and manufacturing, including a wide range of products from chemical drugs to traditional Chinese medicine [1].

Group 1 - Company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise by the Ministry of Industry and Information Technology, which enhances its brand recognition and industry influence [1][2] - The company specializes in chemical pharmaceutical raw materials and intermediates, which are crucial components of the pharmaceutical manufacturing industry, positioned upstream in the supply chain [1] - The company has cultivated a range of high-market-share products, including Sulfate Aluminum, Paracetamol, Atorvastatin Calcium, and PHBA, while expanding sales and market share for products like Escitalopram Oxalate and Parecoxib Sodium in recent years [1] Group 2 - The company has over 20 years of experience in the pharmaceutical industry, focusing on innovation, quality control, and reliable commercial reputation, which strengthens its core competitiveness and market influence [2] - The company has received multiple honors, including recognition as a "specialized and innovative" small enterprise in Zhejiang Province and various awards for quality and contribution to the local economy [2] - The company emphasizes technological innovation and has established a technical innovation system, collaborating with research institutions and universities to enhance R&D capabilities and market value realization [3] Group 3 - The company is committed to continuous R&D, production, and promotion of excellent pharmaceutical products and services, aiming to improve the quality of life [3] - The company plans to focus on the R&D, production, and sales of chemical pharmaceutical raw materials, intermediates, and formulations, pursuing a specialized development path [3] - The establishment of a pilot workshop will create an industrial R&D platform, facilitating the scaling up of new products and enhancing production capacity [3]

Core Viewpoint - Haosen Pharmaceutical reported a revenue of 242 million yuan for the first half of 2025, marking a year-on-year growth of 14.93%, and a net profit attributable to shareholders of 60.79 million yuan, up 4.74% year-on-year [1] Financial Performance - Revenue for the reporting period reached 242 million yuan, reflecting a year-on-year increase of 14.93% [1] - Net profit attributable to shareholders was 60.79 million yuan, showing a year-on-year growth of 4.74% [1] Product and Market Development - The company’s main products include chemical pharmaceutical raw materials and intermediates, which are crucial components of the pharmaceutical manufacturing industry [1] - There is a strong market demand for the company’s main products, with sufficient orders leading to a favorable supply-demand situation [1] - The company is optimizing production capacity to ensure stable supply and is actively enhancing its market development efforts in regions such as the Americas and Europe [1] Research and Development - Haosen Pharmaceutical maintains a high level of investment in research and development, with R&D expenses amounting to 17.71 million yuan, which is 7.32% of its revenue, representing a year-on-year increase of 52.83% [1] - As of the end of the reporting period, the company has 17 products under research, including raw materials, intermediates, and formulation products [1]